Phil Cowdy - Smith Nephew President

SNN Stock  USD 25.78  0.07  0.27%   

President

Mr. Phil Cowdy is Executive Vice President of Business Development Corporationrationrate Affairs of the Company. He joined Smith Nephew in 2008 as Director of Investor Relations. From 2010 his responsibility expanded as Head of Corporationrationrate Affairs, including media, investor relations, global brand and government affairs, together with Strategic Planning. Between 2015 and 2018 he was also responsible for IT. In 2018 he took on additional responsibility for Business Development. He is based in London, UK. Skills and experience Prior to joining Smith Nephew, Phil served as a senior Director at Deutsche Bank for 13 years, providing corporate finance and equity capital markets advice to a variety of UKbased companies. He qualified as a chartered accountant with EY. since 2019.
Age 53
Tenure 5 years
Address Building 5, Watford, United Kingdom, WD18 8YE
Phone44 1923 477 100
Webhttps://www.smith-nephew.com

Smith Nephew Management Efficiency

The company has Return on Asset of 0.0451 % which means that on every $100 spent on assets, it made $0.0451 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0584 %, implying that it generated $0.0584 on every 100 dollars invested. Smith Nephew's management efficiency ratios could be used to measure how well Smith Nephew manages its routine affairs as well as how well it operates its assets and liabilities. As of the 1st of December 2024, Return On Tangible Assets is likely to drop to 0.04. In addition to that, Return On Capital Employed is likely to drop to 0.05. At this time, Smith Nephew's Intangibles To Total Assets are very stable compared to the past year. As of the 1st of December 2024, Asset Turnover is likely to grow to 0.94, while Intangible Assets are likely to drop about 817 M.
Smith Nephew SNATS has 3.08 B in debt with debt to equity (D/E) ratio of 0.54, which is OK given its current industry classification. Smith Nephew SNATS has a current ratio of 1.74, which is typical for the industry and considered as normal. Note however, debt could still be an excellent tool for Smith to invest in growth at high rates of return.

Similar Executives

Showing other executives

PRESIDENT Age

Carter HoughtonInteger Holdings Corp
55
Stanley IIICONMED
49
Stanley PetersCONMED
45
Alex ThurmanGlaukos Corp
54
David DemskiGlobus Medical
62
Franco PolettiLivaNova PLC
N/A
Daniel JonasCONMED
56
Peter ShagoryCONMED
55
David MurrayCONMED
76
Kelli HowellAlphatec Holdings
50
Johonna PelletierCONMED
51
Juergen SregaBruker
69
Kirk ThorInteger Holdings Corp
60
Paul BuckmanLivaNova PLC
68
Keyna SkeffingtonLivaNova PLC
61
Anthony BishopCochLear Ltd ADR
N/A
Joseph GilliamGlaukos Corp
48
Heather CohenCONMED
51
Scott LishAlphatec Holdings
45
David SponselAlphatec Holdings
44
Daniel ScavillaGlobus Medical
59
Smith Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. Smith Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom. Smith Nephew operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 18000 people. Smith Nephew SNATS (SNN) is traded on New York Stock Exchange in USA. It is located in Building 5, Watford, United Kingdom, WD18 8YE and employs 18,000 people. Smith Nephew is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Smith Nephew SNATS Leadership Team

Elected by the shareholders, the Smith Nephew's board of directors comprises two types of representatives: Smith Nephew inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Smith. The board's role is to monitor Smith Nephew's management team and ensure that shareholders' interests are well served. Smith Nephew's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Smith Nephew's outside directors are responsible for providing unbiased perspectives on the board's policies.
Bob White, Non-Executive Independent Director
Alison Parkes, Chief Officer
Skip Kiil, President - Orthopedics
Erik Engstrom, Non-Executive Independent Director
Deepak Nath, Chief Executive Officer
Marc Owen, Non-Executive Independent Director
AnneFrancoise Nesmes, Chief Financial Officer, Executive Director
Helen Barraclough, Company Counsel
Elga Lohler, Chief Human Resource Officer
Bradley Cannon, President Orthopaedics
Roland Diggelmann, Chief Executive Officer, Executive Director
Vinita Bali, Non-Executive Independent Director
Simon Fraser, President - Advanced Wound Management and Global Commercial Operations
John Rogers, CFO Director
Cathy ORourke, Chief Legal and Compliance Officer
Ian Melling, Interim Chief Financial Officer
Roberto Quarta, Non-Executive Independent Chairman of the Board
Joe Metzger, Senior Communications
Katarzyna MazurHofsaess, Non-Executive Independent Director
Rick Medlock, Non-Executive Independent Director
Peter Coenen, President - EMEA Region
Robin Freestone, Senior Non-Executive Independent Director
Paul Connolly, President Operations
Virginia Bottomley, Non-Executive Independent Director
Phil Cowdy, Executive Vice President of Business Development & Corporate Affairs
Angie Risley, Non-Executive Independent Director
Myra Eskes, President - Asia Pacific
Mark Gladwell, President - Global Operations and Global Business Services
John Ma, Non-Executive Independent Director
Andrew Swift, Vice Relations
Vasant Padmanabhan, President - Research & Development
Susan Swabey, Company Secretary
Melissa Guerdan, Chief Quality and Regulatory Affairs Officer
Philip Cowdy, Chief Officer
Steve Kane, Global US
Brad Cannon, President - Sports Medicine & ENT
Jo Hallas, Non-Executive Director
Catheryn ORourke, Chief Legal and Compliance Officer

Smith Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Smith Nephew a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Smith Nephew

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Smith Nephew position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Smith Nephew will appreciate offsetting losses from the drop in the long position's value.

Moving together with Smith Stock

  0.68CI Cigna CorpPairCorr

Moving against Smith Stock

  0.94MD Mednax IncPairCorr
  0.85ELMD ElectromedPairCorr
  0.81VREX Varex Imaging CorpPairCorr
  0.8OM Outset MedicalPairCorr
  0.78DOCS DoximityPairCorr
The ability to find closely correlated positions to Smith Nephew could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Smith Nephew when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Smith Nephew - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Smith Nephew SNATS to buy it.
The correlation of Smith Nephew is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Smith Nephew moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Smith Nephew SNATS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Smith Nephew can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Smith Nephew SNATS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Smith Nephew's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Smith Nephew Snats Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Smith Nephew Snats Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Smith Nephew SNATS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Smith Nephew. If investors know Smith will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Smith Nephew listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.244
Dividend Share
0.375
Earnings Share
0.7
Revenue Per Share
2.5904
Quarterly Revenue Growth
0.034
The market value of Smith Nephew SNATS is measured differently than its book value, which is the value of Smith that is recorded on the company's balance sheet. Investors also form their own opinion of Smith Nephew's value that differs from its market value or its book value, called intrinsic value, which is Smith Nephew's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Smith Nephew's market value can be influenced by many factors that don't directly affect Smith Nephew's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Smith Nephew's value and its price as these two are different measures arrived at by different means. Investors typically determine if Smith Nephew is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Smith Nephew's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.